Valuation: Thalia Therapeutics Plc

Market Cap 10.21M 13.68M 12.25M 11.27M 19.09M 1.3B 19.44M 134M 53.95M 683M 51.34M 50.24M 2.15B P/E 2024
-1.69x
P/E 2025 -3.09x
Enterprise Value 9.13M 12.23M 10.96M 10.08M 17.07M 1.16B 17.39M 120M 48.24M 611M 45.91M 44.93M 1.93B EV / Sales 2024
198,657,512x
EV / Sales 2025 452,941,079x
Free-Float
41.35%
Yield 2024 *
-
Yield 2025 -
1 month-8.00%
3 months-14.81%
Current year+9.52%
1 week 0.55
Extreme 0.55
0.6
1 month 0.55
Extreme 0.55
0.65
Current year 0.4
Extreme 0.4
0.95
1 year 0.4
Extreme 0.4
0.95
3 years 0.35
Extreme 0.35
1.5
5 years 0.35
Extreme 0.35
8.69
10 years 0.35
Extreme 0.35
35.7
Manager TitleAgeSince
Chief Executive Officer 66 24/02/2026
Chief Operating Officer - -
Chief Tech/Sci/R&D Officer 56 27/05/2025
Director TitleAgeSince
Director/Board Member 48 14/07/2020
Chairman 59 01/08/2023
Director/Board Member 81 09/09/2024
Date Insider Type Main position Quantity % Market Cap. Importance
28/11/24 Free

Founder

6,000,000 1.5198%
28/11/24 Free

Director

3,000,000 0.7599%
28/11/24 Free

Chairman

3,000,000 0.7599%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-4.17%-34.29% 13.68M
-0.62%-1.87%+42.87%+64.15% 63.77B
+0.35%+3.20%+14.40%+81.76% 56.37B
+0.53%+1.96%+16.24%+103.35% 54.62B
-2.81%-4.31%+23.50%+47.83% 44.06B
-0.33%-1.93%+19.28%+98.80% 42.11B
+0.55%+2.31%+225.14%+866.21% 41B
+3.27%+47.96%+112.84%+96.58% 34.92B
+1.22%-1.44%+14.57%+46.95% 32.82B
+0.89%+20.55%-40.62%+349.24% 24.7B
Average +0.31%+6.79%+42.40%+172.06% 39.44B
Weighted average by Cap. +0.18%+5.44%+47.99%+176.66%

Financials

2024 2025
Net sales 0.01 0.01 0.01 0.01 0.01 0.93 0.01 0.1 0.04 0.49 0.04 0.04 1.54 0.01 0.01 0.01 0.01 0.01 0.92 0.01 0.1 0.04 0.49 0.04 0.04 1.53
Net income -1.06M -1.42M -1.27M -1.17M -1.98M -135M -2.02M -13.93M -5.59M -70.84M -5.32M -5.21M -223M -1.21M -1.61M -1.45M -1.33M -2.25M -153M -2.29M -15.86M -6.37M -80.63M -6.06M -5.93M -254M
Net Debt -626K -839K -751K -691K -1.17M -79.63M -1.19M -8.24M -3.31M -41.89M -3.15M -3.08M -132M -1.08M -1.45M -1.29M -1.19M -2.02M -137M -2.06M -14.21M -5.7M -72.22M -5.43M -5.31M -228M
Projected Income Statement - Annual - Thalia Therapeutics Plc
Logo Thalia Therapeutics Plc
Thalia Therapeutics PLC, formerly N4 Pharma plc, is a biotechnology company developing RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease. The Company is developing proprietary RNA delivery technologies (Nuvec) designed to enable multi-RNA loading, flexible targeting and the potential for oral delivery. Nuvec is based on amorphous silica and has an irregular surface structure that simply and effectively traps and protects RNA as it travels to target cells. The Nuvec delivery system can be functionalized by attaching a wide range of proteins, peptides, antibodies or radionuclides for therapeutic purposes. The Company has a growing pipeline of RNA-based programs across oncology and cardiovascular disease, including Dual-target cardiovascular siRNA program and Proprietary RNA delivery technology. The Company is advancing a novel long-duration, dual-acting siRNA program targeting PCSK9 and lipoprotein.
Employees
3
Date Price Change Volume
30/10/26 GBX 0.5750 -.--% 20,000
29/10/26 GBX 0.5750 -.--% 753,928
28/10/26 GBX 0.5750 -.--% 300,356
27/10/26 GBX 0.5750 -.--% 1,259,868
26/10/26 GBX 0.5750 -.--% 536,216
  1. Stock Market
  2. Stocks
  3. THAT Stock